Genfit S.A. (GNFTF)

Market Cap	765.07M +295.5%
Revenue (ttm)	83.18M +0.2%
Net Income	-100.94M
EPS	-2.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	49.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	15.95
Previous Close	10.75
Day's Range	15.95 - 15.95
52-Week Range	3.72 - 15.95
Beta	1.14
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About Genfit

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 161
• Stock Exchange: OTCMKTS
• Ticker Symbol: GNFTF

Financial Performance

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error